ArticleViruses2022
Evaluation of the Immunogenicity in Mice Orally Immunized with Recombinant
Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Genetically Modified Lactic Acid Bacteria: a Promising Mucosal Delivery Vector for Vaccines.Probiotics and antimicrobial proteins · 2026Review
- Swine Enteric Coronaviruses: An Updated Overview of Epidemiology, Diagnosis, Prevention, and Control.Animals : an open access journal from MDPI · 2026Review
- Farm animal coronaviruses: the solution is in vaccines.The veterinary quarterly · 2025Review
- Epidemiological investigation, isolation, and pathogenicity of porcine epidemic diarrhea virus subtype G2c in Sichuan province.Archives of virology · 2025Article
- Advances in porcine epidemic diarrhea virus research: genome, epidemiology, vaccines, and detection methods.Discover nano · 2025Review
- Next-Generation Vaccines for Co-Circulating PEDV and TGEV: Integrating Nucleic Acid Platforms, Mucosal Delivery, and AI-Driven Antigen Design.Transboundary and emerging diseases · 2025Review
- Recent Advances in Oral Vaccines for Animals.Veterinary sciences · 2024Review
- Assessing immunogenicity of CRISPR-NCas9 engineered strain against porcine epidemic diarrhea virus.Applied microbiology and biotechnology · 2024Article
- Article
- Prevention and Control of Swine Enteric Coronaviruses in China: A Review of Vaccine Development and Application.Vaccines · 2023Review
- Construction and immunogenicity of a trypsin-independent porcine epidemic diarrhea virus variant.Frontiers in immunology · 2023Article
- Gut microbiome and human health: Exploring how the probiotic genusFrontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine epidemic diarrhea (PED), characterized by diarrhea, vomiting, and dehydration, is an acute enteric infectious disease of pigs. The disease is caused by porcine epidemic diarrhea virus (PEDV), which infects the intestinal mucosal surface. Therefore, mucosal immunization through the oral route is an effective method of immunization. Lactic acid bacteria, which are acid resistant and bile-salt resistant and improve mucosal immunity, are ideal carriers for oral vaccines. The S1 glycoprotein of PEDV mediates binding of the virus with cell receptors and induces neutralizing antibodies against the virus. Therefore, we reversely screened the recombinant strain pPG-SD-S1/Δ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.